AKT1 and myeloproliferative disorder: As a whole, these results, indicating sensitivity of MPN cells to mTOR inhibitors, provided mechanistic explanation for the findings of a phase I/II trial that showed efficacy of RAD001 (Everolimus) against splenomegaly and symptomatic burden in patients with myelofibrosis [54] and reinforce the rationale for designing clinical trials with novel, and possibly more effective, drugs targeting the activated PI3K/Akt/mTOR pathway.